Daxor CORP

Daxor Corporation shareholders re-elected six directors and ratified the appointment of their independent auditor at the 2026 Annual Meeting.

Daxor Corporation completed a registered direct offering, raising approximately $8.14 million in net proceeds through the sale of 765,958 common shares at $11.75 each.

Daxor Corporation has filed its current investor presentation as an exhibit to a Form 8-K, making it available to investors.

Daxor Corporation announced FDA 510(k) clearance for its next-generation rapid, portable lab-based Blood Volume Analysis (BVA) system, poised to significantly improve patient outcomes.

Daxor Corporation announced the results of its Annual Meeting held on June 24, 2025, confirming the re-election of all six directors and the ratification of Bush & Associates, CPA as its independent registered public accounting firm.

Daxor Corporation held its annual meeting on July 15, 2024, electing directors and ratifying its independent auditor.

Daxor Corp's Chief Financial Officer, Robert J. Michel, acquired 12,000 shares of common stock, with vesting scheduled for June 23, 2026.

Daxor Corp CEO Michael Feldschuh acquired 30,000 shares of company stock, with vesting scheduled for June 23, 2026.

Daxor Corp. Chief Scientific Officer Jonathan Feldschuh acquired 25,000 shares of common stock.

Daxor Corp director Joy S. Goudie was granted stock options contingent on SEC approval of an amended incentive plan.

Daxor Corp Director Henry Cremisi was granted stock options contingent on SEC approval of an amended incentive plan.

Daxor Corp director Edward Feuer has been granted stock options contingent on SEC approval of an amended incentive plan.

Daxor Corporation has issued its proxy statement for the Annual Meeting of Stockholders scheduled for June 23, 2026, detailing proposals for director elections and auditor ratification.

Daxor Corporation announced its Annual Meeting of Stockholders for June 24, 2025, to elect six directors and ratify the appointment of Bush & Associates, CPA as its independent registered public accounting firm for the fiscal year ending December 31, 2025.

Daxor Corporation will hold its Annual Meeting of Stockholders on July 15, 2024, to elect directors and ratify the appointment of its independent registered public accounting firm.